References
- SaultzJNRamiroGAcute myeloid leukemia: a concise reviewJ Clin Med201653E3326959069
- HowladerNNooneAMKrapchoMSEER Cancer Statistics Review, 1975–2014Bethesda, MD, USANational Cancer Institute Available from: http://seer.cancer.gov/csr/1975_2013/Accessed February 28, 2018
- DohnerHWeisdorfDJBloomfieldCDAcute myeloid leukemiaN Engl J Med2015373121136115226376137
- VardimanJWThieleJArberDAThe 2008 revision of the world health organization (WHO) classification of myeloid neoplasms in acute leukemia: rationale and important changesBlood2009114593795119357394
- DohnerHEsteyEHAmadoriADiagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNetBlood2010115345347419880497
- FurlongPBridgesJFPCharnasLHow a patient advocacy group developed the first proposed graft guidance document for industry for submission to the US Food and Drug AdministrationOrphanet J Rare Dis2015108226104810
- PerfettoEMBurkeLOehrleinEMEpsteinRSPatient-focused drug development: a new direction for collaborationMed Care201553191725494232
- HoMPGonzalezJMLernerHPIncorporating patient-preference evidence into regulatory decision makingSurg Endosc2015292984299325552232
- HollinILPeayHLApkonSDBridgesJFPatient-centered benefit-risk assessment in duchenne muscular dystrophyMuscle Nerve201755562663427649378
- FoodUSAdministrationDrugStructured approach to benefit-risk assessment in drug regulatory decision-making: draft PDUFA V implementation plan–February 2013. Fiscal Years 2013-2017 Available from: https://www.fda.gov/downloads/ForIndustry/UserFees/PrescriptionDrugUserFee/UCM329758.pdfAccessed February 28, 2018
- FoodUSAdministrationDrugThe voice of the patient. A series of reports from the US Food and Drug Administration’s (FDA’s) Patient-Focused Drug Development InitiativeLung Cancer Available from: http://wayback.archive-it.org/7993/20171114193841/https://www.fda.gov/ForIndustry/UserFees/PrescriptionDrugUserFee/ucm353273.htmAccessed February 28, 2018
- PeayHLHollinILBridgesJFPPrioritizing parental worry associated with duchenne muscular dystrophy using best-worst scalingJ Genet Counsel201625305313
- van TilJAIjzermanMJWhy should regulators consider using patient preferences in benefit-risk assessment?Pharmacoeconomics20143211424288209
- HunterNLO’CallaghanKMCalifRMEngaging patients across the spectrum of medical product development: view from the US Food and Drug AdministrationJAMA20153142499250026584067
- Medical Device Innovation Consortium (MDIC)Patient Centered Benefit-Risk Project Report: A Framework for Incorporating Information on Patient Preferences Regarding Benefit Risk into Regulatory Assessments of New Medical TechnologyMinneapolis, MNMDIC2015
- HauberABFairchildAOJohnsonRQuantifying benefit-risk preferences for medical interventions: an overview of a growing empirical literatureAppl Health Econ Health Policy201311431932923637054
- FoodUSAdministrationDrugThe voice of the patient. A series of reports from the US Food and Drug Administration’s (FDA’s) Patient-Focused Drug Development InitiativeBreast Cancer Available from: http://www.fda.gov/downloads/Drugs/NewsEvents/UCM464932.pdfAccessed February 28, 2018
- JanssenEMSegalJBBridgesJFPA framework for instrument development of a choice experiment: an application to type 2 diabetesPatient20169546547927120338
- HollinILYoungCHansonCBridgesJFPeayHDeveloping a patient-centered benefit-risk survey: a community engaged processValue Health2016166751757
- OakesAHGarmoVSBoneLRLongoDRSegalJBBridgesJFPIdentifying and prioritizing the barriers and facilitators to the self- management of type 2 diabetes mellitus: a community-centered approachPatient201710677378328510080
- JanssenEMBridgesJFPArt and science of instrument development for stated-preference methodsPatient201710437737928616767
- LouviereJJWoodworthGDesign and analysis of simulated consumer choice or allocation experiments: an approach based on aggregate dataJ Market Res1983204350367
- dosReisSNgXFroschEReevesGCunninghamCBridgesJFPUsing best-worst scaling to measure caregiver preferences for managing their child’s ADHD: a pilot studyPatient20158542343125392024
- PotoglouDBurgePFlynnTBest–worst scaling vs. discrete choice experiments: an empirical comparison using social care dataSoc Sci Med201172101717172721530040
- GallegoGBridgesJFPFlynnTBlauveltBMNiessenLWUsing best-worst scaling in horizon scanning for hepatocellular carcinoma technologiesInt J Technol Assess Health Care201262818911901
- LouviereJJFlynnTNUsing best-worst scaling choice experiments to measure public perceptions and preferences for healthcare reform in AustraliaPatient2010327528322273434
- O’DonoghueBBringing the patient voice into drug development Available from: https://www.lls.org/blog/message-to-the-fda-incorporate-patient-voice-into-drug-developmentAccessed February 28, 2018